Legal & General Group’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.3K | Hold |
3,969
| – | – | ﹤0.01% | 3058 |
|
|
2025
Q4 | $15.6K | Hold |
3,969
| – | – | ﹤0.01% | 3120 |
|
|
2025
Q3 | $18.5K | Hold |
3,969
| – | – | ﹤0.01% | 3074 |
|
|
2025
Q2 | $12.3K | Sell |
3,969
-15,276
| -79% | -$49.3K | ﹤0.01% | 3208 |
|
|
2025
Q1 | $65K | Hold |
19,245
| – | – | ﹤0.01% | 2702 |
|
|
2024
Q4 | $109K | Buy |
19,245
+7,597
| +65% | +$49K | ﹤0.01% | 2717 |
|
|
2024
Q3 | $68.1K | Buy |
11,648
+1,797
| +18% | +$13.1K | ﹤0.01% | 2761 |
|
|
2024
Q2 | $77.9K | Buy |
9,851
+4,941
| +101% | +$41.4K | ﹤0.01% | 2752 |
|
|
2024
Q1 | $45.7K | Buy |
4,910
+602
| +14% | +$5.08K | ﹤0.01% | 2787 |
|
|
2023
Q4 | $36.4K | Hold |
4,308
| – | – | ﹤0.01% | 2855 |
|
|
2023
Q3 | $33.4K | Sell |
4,308
-410
| -9% | -$3.74K | ﹤0.01% | 2911 |
|
|
2023
Q2 | $54K | Buy |
+4,718
| New | +$48.8K | ﹤0.01% | 2867 |
|
|
2021
Q2 | – | Sell |
-4,627
| Closed | -$22K | – | 3656 |
|
|
2021
Q1 | $22K | Buy |
4,627
+784
| +20% | +$5.35K | ﹤0.01% | 3105 |
|
|
2020
Q4 | $27K | Hold |
3,843
| – | – | ﹤0.01% | 2983 |
|
|
2020
Q3 | $41K | Sell |
3,843
-1,010
| -21% | -$11.9K | ﹤0.01% | 2760 |
|
|
2020
Q2 | $61K | Buy |
4,853
+39
| +0.8% | +$454 | ﹤0.01% | 2675 |
|
|
2020
Q1 | $44K | Sell |
4,814
-848
| -15% | -$9.73K | ﹤0.01% | 2637 |
|
|
2019
Q4 | $79K | Buy |
5,662
+915
| +19% | +$13.3K | ﹤0.01% | 2669 |
|
|
2019
Q3 | $81K | Hold |
4,747
| – | – | ﹤0.01% | 2592 |
|
|
2019
Q2 | $130K | Buy |
4,747
+1,091
| +30% | +$25K | ﹤0.01% | 2457 |
|
|
2019
Q1 | $70K | Buy |
3,656
+457
| +14% | +$5.95K | ﹤0.01% | 2608 |
|
|
2018
Q4 | $30K | Hold |
3,199
| – | – | ﹤0.01% | 2909 |
|
|
2018
Q3 | $61K | Hold |
3,199
| – | – | ﹤0.01% | 2683 |
|
|
2018
Q2 | $63K | Buy |
3,199
+264
| +9% | +$5.22K | ﹤0.01% | 2653 |
|
|
2018
Q1 | $55K | Sell |
2,935
-1,425
| -33% | -$30.8K | ﹤0.01% | 2713 |
|
|
2017
Q4 | $72K | Sell |
4,360
-141
| -3% | -$2.42K | ﹤0.01% | 2735 |
|
|
2017
Q3 | $92K | Buy |
4,501
+987
| +28% | +$11.1K | ﹤0.01% | 2693 |
|
|
2017
Q2 | $32K | Hold |
3,514
| – | – | ﹤0.01% | 3023 |
|
|
2017
Q1 | $46K | Sell |
3,514
-538
| -13% | -$6.53K | ﹤0.01% | 2887 |
|
|
2016
Q4 | $52K | Buy |
4,052
+1,911
| +89% | +$24.5K | ﹤0.01% | 2882 |
|
|
2016
Q3 | $26K | Hold |
2,141
| – | – | ﹤0.01% | 2774 |
|
|
2016
Q2 | $23K | Buy |
+2,141
| New | +$26.2K | ﹤0.01% | 2816 |
|
Other funds holding VYGR
AC
VPC
VCM
OM
EAM
Legal & General Group's VYGR Position: Q1 2026 in Review
Legal & General Group held its Voyager Therapeutics (VYGR) position steady in Q1 2026 at 3,969 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3058.
Legal & General Group first reported a position in VYGR in Q2 2016 and has held it in 32 quarters since. The position peaked at $130K in Q2 2019. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.
- Legal & General Group held 3,969 shares of Voyager Therapeutics worth $15.3K as of Q1 2026.
- Legal & General Group left its Voyager Therapeutics share count unchanged in Q1 2026.
- Voyager Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3058 holding.
- Legal & General Group first reported a position in Voyager Therapeutics in Q2 2016 and has held it in 32 quarters since.
- Legal & General Group's Voyager Therapeutics position peaked at $130K in Q2 2019.
- 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.